Pay in 4 interest-free payments of $7.24 Learn more
Ships within 48 hours · Estimated delivery Nov 6 - Nov 11
Total Revenue: $15.4B Founded Year: 1916 Total Employees: 29,900 Headquarters: Melbourne, Australia Market Cap: $47.64B Stock Exchange: ASX CSL is a global biotechnology company focused on developing and delivering plasma-derived therapies, vaccines, and specialty medicines, operating through key segments like CSL Behring, CSL Seqirus, and CSL Vifor collectively addressing rare diseases, immunology, and infectious diseases
Consistency is everything
Spending on these drugs reached $5.8 billion in 2022, with average prices consistently exceeding $1,500 per prescription, results show
Regular monitoring of inflammatory markers, disease activity scores, and functional status remains essential regardless of concurrent GLP-1 use
Close medical supervision and gradual dose titration are essential
And the result is worse sulfur burps than either factor would produce independently
